Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
| العنوان: | Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial |
|---|---|
| المؤلفون: | Dana E. Connors, Hao Yang, Geoffrey R. Oxnard, Caroline Robert, Gregory V. Goldmacher, Lawrence H. Schwartz, Richard D. Carvajal, Sanja Karovic, Michael L. Maitland, Ying Tang, Firas S. Ahmed, Laurent Dercle, Binsheng Zhao |
| المصدر: | Eur Radiol |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Pembrolizumab, Antibodies, Monoclonal, Humanized, Article, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Melanoma, Pseudoprogression, Response Evaluation Criteria in Solid Tumors, Neuroradiology, medicine.diagnostic_test, business.industry, Incidence (epidemiology), Interventional radiology, General Medicine, medicine.disease, Clinical trial, 030220 oncology & carcinogenesis, Cohort, Immunotherapy, Radiology, business |
| الوصف: | To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS). A total of 221 patients with locally advanced/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study. Radiological assessment of imaging was centrally reviewed to assess tumor response. Incidence of discordance in BOR between RECIST 1.1 and iRECIST as well as rate of pseudoprogression were measured. OS of patients with pseudoprogression was compared with that of those with uncontrolled disease. Of the 221 patients in this cohort, 136 patients developed PD as per RECIST v1.1 and 78 patients with PD continued treatment and imaging beyond initial RECIST 1.1-defined PD. Among the 78 patients who continued therapy and imaging post-progression, RECIST 1.1 and iRECIST were discordant in 10 patients (12.8%) and pseudoprogression was encountered in 14 patients (17.9%). OS of patients with pseudoprogression was longer than that of patients with uncontrolled disease/true progression (29.9 months versus 8.0 months, p value |
| تدمد: | 1432-1084 0938-7994 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3056cd76ab02c8a946b3e7810e2c44efTest https://doi.org/10.1007/s00330-020-07249-yTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3056cd76ab02c8a946b3e7810e2c44ef |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321084 09387994 |
|---|